Longitudinal myocardial T2* mapping to identify anthracycline-induced cardiotoxicity in patients with breast cancer

Motivation: To identify cancer therapy-related cardiac dysfunction (CTRCD) in patients with breast cancer (BC) receiving anthracycline Goal(s): To evaluate longitudinal changes in myocardial T2* and investigate the utility of T2* mapping for identifying CTRCD Approach: Seventy-eight participants with BC receiving anthracyclines were recruited. All participants underwent CMR at baseline, about 3 months and 6months. T2*, T1, T2 and strain were measured and compared. Logistic regression analysis and receiver operating characteristic analysis were used to assess the performance of T2* values in predicting CTRCD Results: T2* decreased, T1 and T2 increased in patients with BC receiving anthracyclines. T2* can predict subsequent CTRCD in these patients. Impact: Myocardial T2* mapping can identify subsequent CTRCD in patients with BC receiving anthracyclines with/without trastuzumab. This may facilitate accurate prediction of cardiotoxicity and personalized treatment decision making in breast cancer.